Loading
Antitumor Immunity / Colorectal Neoplasms · Journal article
Journal of Pharmaceutical and Biomedical Analysis · July 28, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical mechanistic study in rats showing that Xiao-Chai-Hu-Tang (XCHT) alleviates irinotecan-induced intestinal toxicity by restoring gut microbiota balance and metabolic pathways, particularly through short-chain fatty acid metabolism. The findings provide a plausible biological mechanism but remain in the animal model phase and do not constitute evidence ready for clinical implementation without human trials.
Preclinical mechanistic study in animal model with multi-omics analysis and antibiotic depletion model. Colorectal cancer rats with experimentally induced irinotecan (CPT-11) intestinal toxicity; no human subjects.. Intervention: Xiao-Chai-Hu-Tang (XCHT), a classical traditional Chinese medicine formula. Compared with: Irinotecan alone; antibiotic-treated (microbiota-depleted) versus intact microbiota comparison.
XCHT significantly alleviated intestinal toxicity and reduced inflammation in CPT-11-treated rats, with restored intestinal barrier integrity XCHT enhanced antitumor immunity as evidenced by increased CD4⁺/CD8⁺ ratio and promoted Th1 polarization, potentiating CPT-11's antitumor effects XCHT restored dysbiotic microbiota and disturbed metabolome; restored metabolites enriched in unsaturated fatty acid biosynthesis and linoleic acid metabolism
No absolute quantitation of toxicity reduction, immune marker changes, or microbiota/metabolite fold-changes provided Study does not compare XCHT to standard of care (e.g., loperamide, antiemetics) for chemotherapy-induced toxicity
Clinicians should recognize this as preclinical mechanistic evidence for a potential mechanism of XCHT's benefit, but clinical use remains investigational. Human trials are needed before recommending XCHT as adjunctive therapy for irinotecan toxicity in routine CRC care.
A single-centre mechanistic study in a rat model of chemotherapy toxicity using multi-omics; the design is sound but the evidence is preclinical and cannot directly support clinical practice without human trials.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as preclinical mechanistic evidence for a potential mechanism of XCHT's benefit, but clinical use remains investigational. Human trials are needed before recommending XCHT as adjunctive therapy for irinotecan toxicity in routine CRC care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Irinotecan (CPT-11) is a cornerstone chemotherapeutic for advanced colorectal cancer (CRC), but its clinical use is limited by dose-dependent gastrointestinal (GI) toxicity. Xiao-Chai-Hu-Tang (XCHT), a classical traditional Chinese medicine formula, alleviates CPT-11-induced adverse effects, yet its mechanism remains unclear. This study established a CPT-11-induced intestinal toxicity model in CRC rats, using multi-omics analyses (16S rRNA sequencing, fecal metabolomics, SCFA quantification) and an antibiotic depletion model to explore XCHT's mechanism via the gut microbiota-metabolite axis. XCHT significantly alleviated intestinal toxicity, reduced inflammation, and restored intestinal barrier integrity. It also enhanced antitumor immunity, as evidenced by an increased CD4⁺/CD8⁺ ratio and promoted Th1 polarization, and potentiated CPT-11's antitumor effects. XCHT alleviated CPT-11-induced dysbiosis of key bacterial genera and substantially restored the disturbed metabolome, with the restored metabolites primarily enriched in unsaturated fatty acid biosynthesis and linoleic acid metabolism. It also restored SCFA levels and upregulated colonic SCFA receptors/transporter. Correlation analysis revealed that these microbial and metabolic shifts were closely associated with the improvement of intestinal toxicity and antitumor immunity, and XCHT's protective effects depended on an intact gut microbiota. In conclusion, XCHT mitigates CPT-11-induced intestinal injury and enhances immunity by restoring gut microbiota balance and metabolic reprogramming, providing scientific evidence for its clinical use as a complementary therapy for CRC patients on CPT-11.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.